digital health companies glp-1 management The metabolic revolution has arrived How Digital Health Companies Can

299,300 Phase 2 trials of once weekly administration of the amylin receptor agonist, eloralintide, in adults with overweight or obesity and without type 2 diabetes have demonstrated significant weight loss, with a mean decrease in body weight ranging from 916%, compared with 0.4% in the placebo group.301 Combination therapy of amylin and semaglutide has also shown promise in weight management, with over 40% of trial participants achieving a decrease in body weight of 25%

This makes it easier to manage portion sizes and reduce unnecessary snacking, supporting your weight loss or diabetes management goals

PLoS ONE 9 , e111153 (2014)

It was discovered in 2012,[3] by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide.[4] Clinical trials were started in 2015, and phase 3 was completed in 2016.[5] Researchers at the University of Leeds and Novo Nordisk reported in 2017 that it can also be used for the treatment of obesity.[6] It reduces hunger, food craving and body fat.[7] FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour.[8] On December 5, 2017, semaglutide was approved by the US FDA

While GHRH analogs can increase plasma GH concentrations , their continuous stimulation can sometimes lead to serious adverse reactions , including an increased risk of cardiovascular issues